Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p<0.001). Overall survival in patients with COVID-19 diagnosis between January 2020 and August 2020 was significantly lower than those who were diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs 60% vs 61.9%, respectively; p=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.

COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA) / F. Marchesi, J. Salmanton-García, Z. Emarah, K. Piukovics, M. Nucci, A. López-García, Z. Ráčil, F. Farina, M. Popova, S. Zompi, E. Audisio, M. Ledoux, L. Verga, B. Weinbergerová, T. Szotkovski, M.G. Da Silva, N. Fracchiolla, N. De Jonge, G. Collins, M. Marchetti, G. Magliano, C. García-Vidal, M.M. Biernat, J. Van Doesum, M. Machado, F. Demirkan, M. Al-Khabori, P. Žák, B. Víšek, I. Stoma, G. Méndez, J. Maertens, N. Khanna, I. Espigado, G. Dragonetti, L. Fianchi, M.I. Del Principe, A. Cabirta, I. Ormazabal-Vélez, O. Jaksic, C. Buquicchio, V. Bonuomo, J. Batinić, A.S. Omrani, S. Lamure, O. Finizio, N. Fernández, I. Falces-Romero, O. Blennow, R. Bergantim, N. Ali, S. Win, J. Van Praet, M.C. Tisi, A. Shirinova, M. Schönlein, J. Prattes, M. Piedimonte, V. Petzer, M. Navrátil, A. Kulasekararaj, P. Jindra, J. Sramek, A. Glenthøj, R. Fazzi, C. De Ramón-Sánchez, C. Cattaneo, M. Calbacho, N.C. Bahr, S. El-Ashwah, R. Cordoba, M. Hanakova, G. Zambrotta, M. Sciumè, S. Booth, R.N. Rodrigues, M.V. Sacchi, N. García-Poutón, J. Martín-González, S. Khostelidi, S. Gräfe, L. Rahimli, E. Ammatuna, A. Busca, P. Corradini, M. Hoenigl, N. Klimko, P. Koehler, A. Pagliuca, F. Passamonti, O.A. Cornely, L. Pagano. - In: HAEMATOLOGICA. - ISSN 1592-8721. - (2022). [Epub ahead of print] [10.3324/haematol.2022.280847]

COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)

F. Farina;P. Corradini;
2022

Abstract

Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p<0.001). Overall survival in patients with COVID-19 diagnosis between January 2020 and August 2020 was significantly lower than those who were diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs 60% vs 61.9%, respectively; p=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.
Settore MED/15 - Malattie del Sangue
12-mag-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
Haematologica 2022.pdf

accesso riservato

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 3.65 MB
Formato Adobe PDF
3.65 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
10644-Article Text-78214-1-10-20220512.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 3.65 MB
Formato Adobe PDF
3.65 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/934535
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact